Literature DB >> 12877731

Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation.

Y Ito1, H Yoshida, K Nakano, Y Takamura, A Miya, K Kobayashi, T Yokozawa, F Matsuzuka, N Matsuura, K Kuma, A Miyauchi.   

Abstract

AIM: To investigate the expression of syndecan-1 in thyroid neoplasia. Syndecan-1 is a proteoglycan regulating cell adhesion. Previous studies have demonstrated that decreased expression of syndecan-1 is linked to malignant progression. METHODS AND
RESULTS: Syndecan-1 expression in thyroid neoplasia was studied immunohistochemically. Syndecan-1 was expressed in stromal cells as well as neoplastic epithelial cells. Stromal syndecan-1 expression was observed more frequently in papillary carcinomas larger than 10 mm in size than in microcarcinomas and in widely invasive than in minimally invasive follicular carcinomas. Furthermore, poorly differentiated carcinomas showed this phenomenon more than well-differentiated carcinomas, but the expression in undifferentiated carcinomas was similar to that of poorly differentiated carcinomas. Epithelial syndecan-1 expression was more frequently observed in anaplastic (undifferentiated) carcinomas than in papillary and follicular carcinomas. No significant difference in epithelial expression was found between well and poorly differentiated carcinomas, but undifferentiated carcinomas expressed epithelial syndecan-1 more frequently than did poorly differentiated carcinomas.
CONCLUSIONS: These results are in contrast to those previously reported for carcinomas at other sites. It is suggested that the role of syndecan-1 in thyroid carcinomas might be unique. Stromal syndecan-1 expression followed by its epithelial expression is significantly related to progression, including dedifferentiation of thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12877731     DOI: 10.1046/j.1365-2559.2003.01656.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  9 in total

1.  The expression of syndecan-1 is related to the risk of endometrial hyperplasia progressing to endometrial carcinoma.

Authors:  Hyunjin Kim; Dong Soon Choi; Suk-Joon Chang; Jae Ho Han; Churl K Min; Ki-Hong Chang; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2010-03-31       Impact factor: 4.401

2.  Syndecan-1 and E-cadherin expression in differentiated type of early gastric cancer.

Authors:  Mei-Fang Huang; You-Qing Zhu; Zhi-Fen Chen; Jun Xiao; Xin Huang; Yong-Yan Xiong; Gui-Fang Yang
Journal:  World J Gastroenterol       Date:  2005-05-21       Impact factor: 5.742

3.  Prognostic significance of syndecan-1 expression in squamous cell carcinoma of the tonsil.

Authors:  Sung Hak Lee; Eun Ji Choi; Min Sik Kim; Jun Wook Park; Youn Soo Lee; Su Young Kim; Chang Suk Kang
Journal:  Int J Clin Oncol       Date:  2013-04-04       Impact factor: 3.402

Review 4.  Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication.

Authors:  Tünde Szatmári; Rita Ötvös; Anders Hjerpe; Katalin Dobra
Journal:  Dis Markers       Date:  2015-09-01       Impact factor: 3.434

5.  Syndecan-1 expression is associated with tumor size and EGFR expression in colorectal carcinoma: a clinicopathological study of 230 cases.

Authors:  Su Young Kim; Eun Ji Choi; Jeong A Yun; Eun Sun Jung; Seung Taek Oh; Jun Gi Kim; Won Kyung Kang; Sung Hak Lee
Journal:  Int J Med Sci       Date:  2015-01-01       Impact factor: 3.738

6.  The Profile of Heparanase Expression Distinguishes Differentiated Thyroid Carcinoma from Benign Neoplasms.

Authors:  Leandro Luongo Matos; Eloah Rabello Suarez; Thérèse Rachell Theodoro; Damila Cristina Trufelli; Carina Mucciolo Melo; Larissa Ferraz Garcia; Olivia Capela Grimaldi Oliveira; Maria Graciela Luongo Matos; Jossi Ledo Kanda; Helena Bonciani Nader; João Roberto Maciel Martins; Maria Aparecida Silva Pinhal
Journal:  PLoS One       Date:  2015-10-21       Impact factor: 3.240

7.  Aberrant Expression of Syndecan-1 in Cervical Cancers.

Authors:  Katalin Karászi; Renáta Vigh; Miklós Máthé; Alexandra Fullár; Lászlóné Oláh; Tibor Füle; Zoltán Papp; Ilona Kovalszky
Journal:  Pathol Oncol Res       Date:  2020-05-10       Impact factor: 3.201

8.  Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues.

Authors:  Simon Kind; Christina Merenkow; Franziska Büscheck; Katharina Möller; David Dum; Viktoria Chirico; Andreas M Luebke; Doris Höflmayer; Andrea Hinsch; Frank Jacobsen; Cosima Göbel; Sören Weidemann; Christoph Fraune; Christina Möller-Koop; Claudia Hube-Magg; Till S Clauditz; Ronald Simon; Guido Sauter; Waldemar Wilczak; Ahmed Abdulwahab Bawahab; Jakob R Izbicki; Daniel Perez; Andreas Marx
Journal:  Dis Markers       Date:  2019-12-23       Impact factor: 3.434

9.  Syndecan-1 Promotes Hepatocyte-Like Differentiation of Hepatoma Cells Targeting Ets-1 and AP-1.

Authors:  Péter Hollósi; Lóránd Váncza; Katalin Karászi; Katalin Dobos; Bálint Péterfia; Enikő Tátrai; Péter Tátrai; Tibor Szarvas; Sándor Paku; László Szilák; Ilona Kovalszky
Journal:  Biomolecules       Date:  2020-09-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.